Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
15.50
+0.04 (0.26%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 34.5, with a low estimate of 20 and a high estimate of 50. The average target predicts an increase of 122.58% from the current stock price of 15.50.
Analyst Consensus: Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for RCUS stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +29.03% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +87.10% | Oct 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +29.03% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates $20 | Hold | Initiates | $20 | +29.03% | Oct 21, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $29 | Buy | Initiates | $29 | +87.10% | Oct 8, 2024 |
Financial Forecast
Revenue This Year
265.74M
from 117.00M
Increased by 127.13%
Revenue Next Year
216.90M
from 265.74M
Decreased by -18.38%
EPS This Year
-3.45
from -4.15
EPS Next Year
-4.90
from -3.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 285.6M | 606.2M | 540.8M | |||
| Avg | 265.7M | 216.9M | 233.6M | |||
| Low | 239.1M | 29.4M | 88.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 144.1% | 128.1% | 149.3% | |||
| Avg | 127.1% | -18.4% | 7.7% | |||
| Low | 104.4% | -88.9% | -59.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.57 | -3.38 | -1.93 | |||
| Avg | -3.45 | -4.90 | -4.48 | |||
| Low | -4.06 | -6.60 | -6.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.